BlackRock Health Sciences Term Trust
No SEC Form 4 filings for $BMEZ in the last 30 days.
See all $BMEZ insider activity →BlackRock (BLK) announced that its BMEZ fund will offer to buy back up to 5% of its shares at 98% of net asset value (NAV), following a period where the fund traded at a discount of over 10%. This move is part of BlackRock's discount control program, and other funds in the program will not conduct similar tenders.
Robert W. Fairbairn, a Director at BlackRock Health Sciences Term Trust (NYSE:BMEZ), reported selling shares worth a total of $308,420 across December 18 and 19, 2025. The transactions involved both direct and indirect sales (by spouse) of common stock at prices around $14.98 and $14.96 per share. A total of 20,588.422 shares were sold in these transactions.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BMEZ (BlackRock Health Sciences Term Trust). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent BMEZ coverage spans corporate actions and financial news.
The tender could reduce the fund's discount but may not fully close the >10% gap.
The recent sale of approximately 20,588 shares by Robert W. Fairbairn at around $14.97 per share suggests a cautious stance from insider leadership. This could reflect a lack of confidence in near-term performance or a liquidity need.
AlphAI scores every news story that mentions BMEZ with an AI model for sentiment and relevance, and aggregates insider trades from BlackRock Health Sciences Term Trust's SEC EDGAR Form 4 filings. Figures refresh continuously.
BlackRock (BLK) announced that its BMEZ fund will offer to buy back up to 5% of its shares at 98% of net asset value (NAV), following a period where the fund traded at a discount of over 10%. This move is part of BlackRock's discount control program, and other funds in the program will not conduct similar tenders.
2 min readRobert W. Fairbairn, a Director at BlackRock Health Sciences Term Trust (NYSE:BMEZ), reported selling shares worth a total of $308,420 across December 18 and 19, 2025. The transactions involved both direct and indirect sales (by spouse) of common stock at prices around $14.98 and $14.96 per share. A total of 20,588.422 shares were sold in these transactions.
2 min read
